Odomzo
Drug - Odomzo® (sonidegib) [Novartis]
March 2016
Therapeutic area - Basal cell carcinoma
Approval criteria
- Patient is 18 years of age or older AND
- Provider must:
- Verify the pregnancy status of female patient OR
- Advise the risk of exposure of male patient
- Patient has a diagnosis of basal cell carcinoma AND one of the following:
- Disease has recurred after surgery or radiation OR
- Patient is not a candidate for surgery or radiation
Quantity limit
Maximum of 34 capsules per 34 days
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411